Home
Home

Watson

Watson challenges patent on cancer drug Velcade

Watson challenges patent on cancer drug Velcade
PharmPro

Watson CEO Looks Past Actavis Deal to Next Growth Plans

Watson CEO Looks Past Actavis Deal to Next Growth Plans
Bloomberg

Healthcare Business Review: Watson Gets EU Approval, Stryker’s Bad News

Healthcare Business Review: Watson Gets EU Approval, Stryker’s Bad News
Wall Street Cheat Street

Healthcare Business Review: Questcor Defended, Watson’s Recall

Healthcare Business Review: Questcor Defended, Watson’s Recall
Wall Street Cheat Street

9 Rallying Healthcare Stocks Seeing Strong Sales Trends

9 Rallying Healthcare Stocks Seeing Strong Sales Trends
Seeking Alpha

Momenta Loses In Appeals Court Over Watson’s Lovenox Copy

Momenta Loses In Appeals Court Over Watson’s Lovenox Copy
Bloomberg

Nothing Generic About Watson Stock

Nothing Generic About Watson Stock
Barron's

Watson Pharma says federal appeals court agrees 4 Sanctura XR patents are not valid

Watson Pharma says federal appeals court agrees 4 Sanctura XR patents are not valid
Yahoo/AP

China Biotech In Review: A Week Of Big Deals

China Biotech In Review: A Week Of Big Deals
Seeking Alpha

Watson, Actavis to Merge in €4.5 Billion Deal

Watson, Actavis to Merge in €4.5 Billion Deal
WSJ Online